Extracorporeal Or Ex Vivo Removal Of Antibodies Or Immune Complexes (e.g., Removal Of Autoantibodies, Etc.); Or Extracorporeal Or Ex Vivo Removal Of Antigen By Antibodies (e.g., Removal Of Cancer Cells From Bone Marrow By Antibodies, Etc.) Patents (Class 424/140.1)
-
Publication number: 20110002920Abstract: Provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer by administering an effective amount of a soluble form of a co-stimulatory molecule from an antigen presenting cell and by reducing the activity of immunoregulatory T cells in the individual. Methods of reduction in the activity of immunoregulatory T cells involve removing them ex vivo or depleting or inactivating them in vivo. Also provided are cancer therapeutic compositions comprising a soluble form of a co-stimulatory molecule from an antigen presenting cell and an antibody specific for an intracellular antigen.Type: ApplicationFiled: March 25, 2010Publication date: January 6, 2011Inventors: Alan Epstein, Peishing Hu
-
Publication number: 20110002921Abstract: Provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer by administering an effective amount of a soluble form of a co-stimulatory molecule from an antigen presenting cell and by reducing the activity of immunoregulatory T cells in the individual. Methods of reduction in the activity of immunoregulatory T cells involve removing them ex vivo or depleting or inactivating them in vivo. Also provided are cancer therapeutic compositions comprising a soluble form of a co-stimulatory molecule from an antigen presenting cell and an antibody specific for an intracellular antigen.Type: ApplicationFiled: March 25, 2010Publication date: January 6, 2011Inventors: Alan Epstein, Peishing Hu
-
Publication number: 20100310646Abstract: The present invention relates in one embodiment to PAPP-A exosite(s) interactors such as antibodies which bind to a region comprising LNR3 of PAPP-A and efficiently inhibit proteolysis of IGFBP-4, but not -5. The region comprising LNR3 represents a substrate binding exosite, which can be targeted for selective proteolytic inhibition. Accordingly, the present invention relates in one embodiment to differential inhibition of natural protease substrates by exosite targeting.Type: ApplicationFiled: January 23, 2009Publication date: December 9, 2010Inventors: Claus Oxvig, Jakob Hauge Mikkelsen, Claus Gyrup Nielsen
-
Publication number: 20100278832Abstract: BST2 antibodies were selected by using as an indicator the binding between BST2 antibodies and various splicing variants of human BST2 antigen. As a result, the present inventors successfully obtained BST2 antibodies that specifically recognize BST2D, which has been reported to be expressed at high levels in cancer cells. The antibodies of the present invention specifically bind to cells expressing BST2D. Non-specific antibody binding to non-target tissues, which results in the decrease of antibody concentration in blood, can be prevented by using the antibodies of the present invention therapeutically. Alternatively, the present invention provides diagnostic agents comprising an antibody of the present invention, which specifically detect tissues expressing BST2D.Type: ApplicationFiled: October 16, 2008Publication date: November 4, 2010Inventors: Yumiko Kamogawa, Sahori Namiki, Minkwon Cho, Koji Ishida
-
Publication number: 20100203147Abstract: Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering an immunosuppressive agent.Type: ApplicationFiled: April 16, 2010Publication date: August 12, 2010Applicant: ONCOLYTICS BIOTECH INC.Inventors: Matthew C. Coffey, Bradley G. Thompson
-
Patent number: 7744883Abstract: The present invention provides a method, and resulting product, for the removal of unwanted molecules from a host's blood using a one-step procedure. The unwanted molecules may be anti-A blood protein and/or anti-B blood protein antibodies that would otherwise cause host rejection of transplanted organs or tissues from a source having a different ABO blood type. The unwanted molecules may also be excess antibodies, or virions, present in a diseased host.Type: GrantFiled: February 13, 2004Date of Patent: June 29, 2010Assignee: Advanced Extravascular Systems, Inc.Inventor: Duke K Bristow
-
Patent number: 7740849Abstract: Disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using combinations of compounds that alter soluble endoglin and sFlt-1 expression levels or biological activity. Also disclosed are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that increase endothelial nitric oxide synthase levels or biological activity.Type: GrantFiled: May 31, 2006Date of Patent: June 22, 2010Assignees: Beth Israel Deaconess Medical Center, The Hospital for Sick ChildrenInventors: S. Ananth Karumanchi, Vikas P. Sukhatme, Mourad Toporsian, Michelle V. Letarte
-
Patent number: 7718387Abstract: The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.Type: GrantFiled: September 20, 2002Date of Patent: May 18, 2010Assignee: Board of Regents, the University of Texas SystemInventors: Maher Albitar, Michael J. Keating, Taghi Manshouri
-
Publication number: 20100098698Abstract: This invention uses “targeted apheresis” to treat rheumatoid arthritis patients. “Targeted Apheresis” is a process whereby the RF and immune complexes responsible for causing the disease symptoms are selectively removed from the blood by passing the blood through a cartridge containing immobilized IgG. The RF and immune complexes are bound out and the cleaned blood is returned to the patient Removal of circulating RF and immune complexes will ameliorate the symptoms of rheumatoid arthritis.Type: ApplicationFiled: January 5, 2010Publication date: April 22, 2010Inventors: HENRY J. SMITH, James R. Smith
-
Publication number: 20100098688Abstract: The present invention relates to a method for diagnosis of a disease selected from the group of diabetes, vasculitis, collagenosis, an inflammatory rheumatic disease and arteriosclerosis wherein, presence or absence of an anti-AT1-receptor antibody is determined in a sample from a patient to be diagnosed and wherein, the presence of an anti-AT1-receptor antibody is indicative of the disease. The invention further relates to the use of an inhibitor of an anti-AT1-receptor antibody or an inhibitor of an AT1-receptor for the production of a medicament as well as plasmapheresis of blood for the removal of anti-AT1-receptor antibodies.Type: ApplicationFiled: July 31, 2007Publication date: April 22, 2010Applicant: CELLTREND GMBHInventors: Kai Schulze-Forster, Harald Heidecke
-
Patent number: 7666421Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.Type: GrantFiled: December 5, 2005Date of Patent: February 23, 2010Assignee: Genetics Institute, LLCInventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
-
Patent number: 7632807Abstract: The compounds of the present invention are represented by the chemical structure found in Formula I: or a pharmaceutically acceptable salt thereof, with X, R0, and R1 defined herein.Type: GrantFiled: March 12, 2008Date of Patent: December 15, 2009Assignee: Albany Molecular Research, Inc.Inventors: Bruce F. Molino, Zhicai Yang
-
Publication number: 20090246203Abstract: The invention relates to a novel method for immunoadsorption therapy of human autoimmune diseases by means of immobilized or fixed autoantigens.Type: ApplicationFiled: January 24, 2007Publication date: October 1, 2009Inventors: Angelika Lüking, Christian Scheer, Verena Gruss Trappe, Claudia Gutjahr, Kirsten Schulte
-
Patent number: 7595044Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.Type: GrantFiled: January 4, 2005Date of Patent: September 29, 2009Assignee: California Institute of TechnologyInventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
-
Patent number: 7534419Abstract: A method of detecting osteoporosis in a mammalian is disclosed herein which includes: a) obtaining a sample of a bone related tissue or cells; and b) measuring the concentration of at least a marker which is either bacteria, bacteria produced factors, or HSPs. The method may further include comparing the concentration with concentrations from the same individual over a period of time or against a standard concentration. The marker may be a bacteria, a chaperone molecule, or a bacteria produced. Also provided herein is a method of treating or preventing osteoporosis caused by a bone disease which includes administering to a mammalian subject a therapeutically effective amount of a formulation which is either an HSP antigenic formulation or a bacterial antigenic formulation. The osteoporosis can be caused by a bone disease induced by bone infectious agents such as viruses, bacteria, fungi, protozoa and parasites.Type: GrantFiled: January 17, 2002Date of Patent: May 19, 2009Assignee: Depuy Mitek, Inc.Inventors: Kai-Uwe Lewandrowski, Debra J. Trantolo
-
Patent number: 7531175Abstract: The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.Type: GrantFiled: November 12, 2004Date of Patent: May 12, 2009Assignee: Genetics Institute LLCInventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
-
Publication number: 20090074755Abstract: The present invention relates to compositions and methods for treating Staphylococcus aureus (S. aureus) infections. In particular, the present invention provides vaccines comprising a Panton-Valentine Leukocidin (u) antigen, antibodies which bind a PVL antigen and compositions containing the same, methods of making such compositions and methods for treating S. aureus infections, including those that are community acquired methicillin-resistant infections. The present invention also provides PVL antibodies, including PVL antibodies specific for a single PVL subunit, and PVL antigens, including conjugated and mutated PVL antigens.Type: ApplicationFiled: June 13, 2006Publication date: March 19, 2009Inventors: Kimberly Louise Taylor, Ali Ibrahim Fattom
-
Publication number: 20080286278Abstract: A process for treating biological targets in a fluid of a biological organism, including introducing a fluid comprising a biological target to an assembly comprising an inlet connected to receive the fluid and an outlet connected to pass the fluid from the assembly, wherein the assembly comprises a flow chamber for conveying a flow of the fluid, and a capture zone comprising a target-specific binding agent, wherein during flow of the fluid through the flow chamber, the biological target undergoes flux rolling along the target-specific binding agent.Type: ApplicationFiled: July 16, 2008Publication date: November 20, 2008Applicant: BIOMED SOLUTIONS, LLCInventors: Patrick R. Connelly, Jeffrey L. Helfer, Andrew W. Custer, Michael B. Kim
-
Patent number: 7425619Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.Type: GrantFiled: August 14, 2003Date of Patent: September 16, 2008Assignee: MacroGenics, Inc.Inventors: Scott Koenig, Maria Concetta Veri
-
Publication number: 20080075690Abstract: Provided is a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors such as soluble TNF receptor from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partners such as TNF? muteins capable of binding to and, thus, depleting the targeted immune system inhibitors from the biological fluids. Particularly useful is an adsorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as a TNF? mutein, capable of specifically binding to a targeted immune system inhibitor such as soluble TNF receptor.Type: ApplicationFiled: September 22, 2006Publication date: March 27, 2008Inventor: Mark Douglas Howell
-
Publication number: 20080063645Abstract: It is believed that the abnormal absorption of endotoxin present in the gastrointestinal tract relates to the pathogenesis of autoimmune diseases such as rheumatoid arthritis. In an animal model for rheumatoid arthritis, it is observed that arthritis is improved by removing endotoxin. The present invention provides endotoxin-adsorbent, which is capable of removing endotoin in gastrointestinal tract and can be administered to humans safely. By using a non-digestible and non-absorbable, and therefore, safe endotoxin-adsorbent, which has a high endotoxin-binding capacity for removing large amounts of endotoxin present in the gastrointestinal tract, it is possible to prevent and treat autoimmune diseases such as rheumatoid arthritis.Type: ApplicationFiled: September 7, 2006Publication date: March 13, 2008Inventors: Kuniaki Terato, Hiroshi Shionoya, Sadaichi Iwashita
-
Patent number: 7309488Abstract: An adsorbent which comprises a water-insoluble carrier and a compound, which is immobilized on said carrier, having a binding affinity for an antibody against ?1-adrenoceptor and/or an antibody against M2 muscarinic receptor exhibits a remarkably large adsorptive capacity.Type: GrantFiled: April 9, 2001Date of Patent: December 18, 2007Assignee: Kaneka CorporationInventors: Eiji Ogino, Shigeo Furuyoshi, Fumiyasu Hirai, Takehiro Nishimoto
-
Patent number: 7226429Abstract: The present invention relates to a method for using lectins that bind to pathogens having high mannose surface glycoproteins or fragments thereof which contain high mannose glycoproteins, to remove them from infected blood or plasma in an extracorporeal setting. Accordingly, the present invention provides a method for reducing viral load in an individual comprising the steps of obtaining blood or plasma from the individual, passing the blood or plasma through a porous hollow fiber membrane wherein lectin molecules are immobilized within the porous exterior portion of the membrane, collecting pass-through blood or plasma and reinfusing the pass-through blood or plasma into the individual.Type: GrantFiled: January 20, 2004Date of Patent: June 5, 2007Assignee: Aethlon Medical, Inc.Inventor: Richard H. Tullis
-
Patent number: 7201901Abstract: Methods for producing biological solutions such as immunoglobulins and in particular anti-D immunoglobulin substantially free of abnormal prion protein resulting therefrom. Specifically provided are methods for aggregation of prions and depth filtration of the biological solution to capture and remove abnormal and if desired, normal prion protein. The prion protein may then be eluted from the depth filter and filter washes and concentrated sufficient for detection at limits currently required by available assays.Type: GrantFiled: May 23, 2003Date of Patent: April 10, 2007Assignee: Ortho-Clinical Diagnostics, Inc.Inventors: Robert W. Van Holten, Stephen M. Autenrieth
-
Patent number: 7201730Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50–75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: GrantFiled: March 17, 2003Date of Patent: April 10, 2007Assignee: Hemavation, LLCInventors: Alan A. Davidner, Kimberly A. Walker, Scott R. Mallett
-
Patent number: 7202045Abstract: The present invention relates to compositions and methods for cancer therapies and diagnostics, including but not limited to, cancer markers. In particular, the present invention provides tumor antigens associated with specific cancers and diagnostic assays for the detection of such antigens and associated autoantibodies as indicative of the presence of specific cancers. The present invention further provides cancer immunotherapy utilizing the tumor antigens of the present invention.Type: GrantFiled: September 16, 2002Date of Patent: April 10, 2007Assignee: Regents of the University of MichiganInventors: Samir M. Hanash, Franck Brichory
-
Patent number: 7153945Abstract: The present invention provides an adsorbent, adsorption unit, and an adsorption method which make it possible to selectively adsorb an immunoglobulin and/or an immune complex present in a body fluid (for example, blood, plasma, etc.) efficiently without pretreating the body fluid. By immobilizing a compound having binding activity for an immunoglobulin and/or an immune complex on a water-insoluble carrier, an adsorbent having remarkably excellent adsorption capacity may be obtained.Type: GrantFiled: September 18, 2002Date of Patent: December 26, 2006Assignee: Kaneka CorporationInventors: Eiji Ogino, Takehiro Nishimoto, Michio Nomura, Shigeo Furuyoshi
-
Patent number: 7056507Abstract: An adsorbent for removing hepatitis C virus which has the ability to adsorb HCV particles, particularly immune-complex HCV particles, from a patient's body blood safely and with high efficiency and high selectivity for enhancing the efficacy of interferon therapy, an HCV adsorption apparatus including said adsorbent, and a adsorbing method for removing HCV are provided. An adsorbent for removing hepatitis C virus which comprises a compound capable of adsorbing hepatitis C virus as immobilized on a water-insoluble carrier, an adsorption apparatus including said adsorbent, and an adsorbing method for removing HCV.Type: GrantFiled: June 11, 2003Date of Patent: June 6, 2006Assignee: Kaneka CorporationInventors: Eiji Ogino, Michio Nomura, Takashi Asahi, Shuichi Kaneko, Akito Sakai
-
Patent number: 7022322Abstract: Immunoapheresis treatment for cardiomyopathy comprises passing the patient's plasma over a column having coupled thereto a specific ligand for human immunoglobulin, thereby removing a significant portion of the immunoglobulin from the patient's plasma, and then reinfusing the plasma to the patient. The invention is the use of a specific ligand for human immunoglobulin in the manufacture of a column having the ligand coupled thereto, the column being useful for immunoapheresis treatment of a patient with cardiomyopathy. The specific ligand binds, and thereby removes, human autoantibodies which are harmful to cardiac tissue such as antibodies against ?1-adrenergic receptors, ADP-ATP carriers, ? and ? myosin heavy chains, and adenine nucleotide translocators.Type: GrantFiled: November 19, 2002Date of Patent: April 4, 2006Assignee: Edwards Lifesciences CorporationInventors: Robert Koll, Jutta Müller-Derlich, Stephan Felix, Petra Reinke, Stefan Brehme, Gert Baumann, Reiner Spaethe
-
Patent number: 7014854Abstract: A method for treating a condition related to the development of Alzheimer's disease (AD) is disclosed. The method involves the removal of circulating autoantibodies of a biochemical marker or markers, specifically human glial fibrillary acidic protein (GFAP) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), from the sera of a patient in an amount effective to reduce or eliminate phagocytosis of astrocytic cells. The invention further includes a process of immune system modulation effective for autoantibody removal.Type: GrantFiled: December 30, 2002Date of Patent: March 21, 2006Assignee: Syn X Pharma, Inc.Inventors: George Jackowski, Shirley Furesz
-
Patent number: 6994854Abstract: The subject of the invention is amino acid sequences of the AC-Hly from B. pertussis, B. parapertussis and/or B. bronchiseptica, carrying epitopes capable of inducing a protective immune response against infection by Bordetella. The subject of the invention is antibodies, especially monoclonal antibodies, directed against these epitopes.Type: GrantFiled: July 19, 2001Date of Patent: February 7, 2006Assignee: Institut PasteurInventors: Fotini Betsou, Peter Sebo, Nicole Gutso
-
Patent number: 6984383Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.Type: GrantFiled: July 27, 2000Date of Patent: January 10, 2006Assignee: Genetics Institute, LLCInventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
-
Patent number: 6969616Abstract: The present invention is directed to an enterotoxin adsorbent comprising a compound having a log P (P denotes a partition coefficient in an octanol-water system) value of not less than 2.50 as immobilized on a water-insoluble carrier.Type: GrantFiled: September 25, 2001Date of Patent: November 29, 2005Assignee: Kaneka CorporationInventors: Fumiyasu Hirai, Tamiji Fujimoto, Shigeo Furuyoshi
-
Patent number: 6951644Abstract: An adsorbent for peptidoglycan which comprises an water-insoluble porous material having an amino group and having a molecular weight of exclusion limit of at least 50,000, and a method for removing peptidoglycan by adsorption, which comprises a step of contacting the adsorbent to a liquid containing peptidoglycan.Type: GrantFiled: November 30, 2000Date of Patent: October 4, 2005Assignee: Kaneka CorporationInventors: Fumiyasu Hirai, Shigeo Furuyoshi
-
Patent number: 6924361Abstract: This invention relates to growth regulatory proteins expressed in various disease states, especially receptor tyrosine kinases and similar growth factor receptors. Prior to the Applicants invention, it was not clear that specific antibodies could be generated that recognized peptide epitopes comprising phosphotyrosine in the context of its surrounding amino acid sequence. Applicants generated antibodies to such phosphotyrosine specific peptides, distinct from antibodies that recognize only phosphotyrosine itself. The invention includes methods for producing phosphopeptide specific antibodies by removing contaminating antibody specificities by negative and/or positive selections. Phosphospecific antibodies and their uses in immunodetection, diagnostic or therapeutic applications are also disclosed.Type: GrantFiled: November 2, 1993Date of Patent: August 2, 2005Assignee: Phosphoproteomics LLCInventors: Andrew Peter Laudano, David Frederick Stern
-
Patent number: 6881408Abstract: The invention relates to immunoadsorbers for use in sepsis therapy, in particular for removal of complement factors and lipopolysaccharides (LPS) and, if need be, further sepsis mediators such as TNF and interleukins from body fluids, methods for their production and their use.Type: GrantFiled: March 23, 2000Date of Patent: April 19, 2005Assignee: Bioserv AGInventors: Hans-Werner Heinrich, Hans-Jürgen Hahn, Udo Meyer, Peter Kruschke, Heinz-Jürgen Wagner
-
Patent number: 6878127Abstract: Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of pro-inflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators.Type: GrantFiled: December 21, 2001Date of Patent: April 12, 2005Assignee: RenalTech International, LLCInventors: James A Brady, James F Winchester, Vadim Davankov, Maria Tsyurupa, Ludmila Pavlova, Frank M Norris, Peter J Quartararo, Jr., Jamie A Salsberg
-
Patent number: 6866846Abstract: A process for preparing a patient-specific immunoadsorber, which comprises (i) extracting a body fluid from a patient having an immunopathological condition, the fluid containing immune complexes that are relevant to that immunopathological condition, (ii) contacting the extracted fluid with an adsorbent for the immune complexes to form adsorbed immune complexes, (iii) eluting the adsorbed complexes to form an eluate, (iv) fractionating the eluate into a plurality of immune complex component fractions, and (v) immobilizing the immune complex components on one or more biologically compatible carriers activated to bond to its surface one or more desired immune complex components.Type: GrantFiled: April 3, 1998Date of Patent: March 15, 2005Assignee: Privates Institut Bioserv GmbHInventors: Hans-Werner Heinrich, Wolfgang Ramlow, Hans-Friedrich Boeden, Hans-Georg Neumann, Udo Meyer, Joachim Teller
-
Patent number: 6846637Abstract: Anti-Fas (APO-1, CD95) autoantibodies arm found in human s, which antibodies arm biologically functional. Peptide fragments of Fas recognized by such antibodies, and antibodies specific for such peptides, inhibit or promote apoptosis and cellular proliferation. Assay methods making use of Fas peptides or antibodies enable identification of further agents which modulate apoptosis and/or cellular proliferation.Type: GrantFiled: June 15, 1999Date of Patent: January 25, 2005Assignee: IMED ABInventor: Francesca Chiodi
-
Publication number: 20040258672Abstract: The present disclosure provides methods for inducing tolerance in a recipient to a mismatched graft of an organ, tissue and/or cells. By reactivating the recipient's thymus and providing hematopoietic stem cells from the donor, the previously “foreign” matter becomes recognized as “self” in the recipient and is not rejected. The patient's T cell population is depleted. In some embodiments, the hematopoietic stem cells are CD34+. The recipient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In some embodiments, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.Type: ApplicationFiled: December 30, 2003Publication date: December 23, 2004Applicant: Monash UniversityInventor: Richard L. Boyd
-
Publication number: 20040229218Abstract: Immunoassays for detecting hepatitis C virus protein and immune complexes between hepatitis C virus protein and antibodies in biological samples, methods of screening blood products for hepatitis C virus, and kits employed therefor are provided.Type: ApplicationFiled: April 7, 2004Publication date: November 18, 2004Applicant: Chiron CorporationInventors: David Y. Chien, Phillip Arcangel
-
Publication number: 20040208865Abstract: A process for the preparation of active receptor and receptor complex fractions from cell lines expressing cell surface receptors which comprises applying ultrasonication to provide said expression to the cells in an aqueous (detergent free or substantially detergent free) composition and related methods and devices.Type: ApplicationFiled: February 12, 2004Publication date: October 21, 2004Inventor: Anil K. Chauhan
-
Patent number: 6803036Abstract: The field of the invention is generally related to pharmaceutical agents useful in treating graft-versus-host disease (GVHD) in patients that have received allogenic bone marrow transplants.Type: GrantFiled: September 1, 2000Date of Patent: October 12, 2004Assignee: University of Southern CaliforniaInventor: David A. Horwitz
-
Publication number: 20040191245Abstract: The invention provides a method of depleting anti-MHC antibodies in a sample comprising contacting said sample with one or more recombinant MHC molecules or functionally equivalent variants, derivatives or fragments thereof and removing at least the recombinant MHC molecules to which antibodies to said recombinant MHC molecules contained within the sample have bound. This method allows the depletion of one or more specific MHC particularly HLA allele antibodies from a sample.Type: ApplicationFiled: July 22, 2003Publication date: September 30, 2004Inventors: Martin C. M. M. Barnardo, Andrea W. Harmer, Michael Bunce, Robert W. Vaughan, Kenneth I. Welsh
-
Publication number: 20040191246Abstract: A process for the in vivo treatment of the bodily fluid of a biological organism is presented, wherein the organism is implanted with a capture device containing a target specific binding agent. The bodily fluid of the donor is brought into contact with the binding agent and the desired cellular components are allowed to bind with the binding agent.Type: ApplicationFiled: February 26, 2004Publication date: September 30, 2004Inventors: Patrick R. Connelly, Jeffrey L. Helfer, Andrew W. Custer, Michael B. Kim
-
Publication number: 20040186410Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: ApplicationFiled: March 17, 2003Publication date: September 23, 2004Inventors: Alan A. Davidner, Kimberly A. Walker, Scott R. Mallett
-
Publication number: 20040185042Abstract: This invention relates to adsorbents and methods for highly selective removal of anti-von Willebrand Factor-cleaving protease antibodies (“anti-vWF-cp-abs”) from human plasma using human von Willebrand Factor-cleaving protease (“hvWF-cp”) or fragments thereof as affinity ligands. The adsorbents can be used for treating disorders associated with the occurrence of anti-vWF-cp-abs in patients, such as thromboembolic diseases.Type: ApplicationFiled: March 20, 2003Publication date: September 23, 2004Inventors: Friedrich Scheiflinger, Barbara Plaimauer, Gerhard Antoine
-
Publication number: 20040185041Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: ApplicationFiled: March 17, 2003Publication date: September 23, 2004Applicant: Henna Vation, LLCInventors: Kimberly A. Walker, Alan A. Davidner, Scott R. Mallett
-
Publication number: 20040185043Abstract: The primary focus of this the present invention is to disclose a minimal conditioning approach to establish mixed chimerism to induce tolerance in recipients having autoimmune disease. Engraftment is multifactorial. Both donor and host factors influence engraftment as independent but complementary variables. By optimizing first the donor factors that influence outcome and then defining the recipient factors that resist engraftment. Chimerisms in recipients with minimum morbidity can be achieved, thus allowing for the prevention or treatment of autoimmune disease.Type: ApplicationFiled: November 5, 2003Publication date: September 23, 2004Inventor: Suzanne T. Ildstad
-
Publication number: 20040186411Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: ApplicationFiled: March 17, 2003Publication date: September 23, 2004Inventors: Scott R. Mallett, Alan A. Davidner, Kimberly A. Walker